Q2 2025
Released Aug 7, 2025, before the open
10-Q filed Aug 7, 2025, 38 days after period end · 0001628280-25-038619
Q2 2025 · 10-Q
Revenue$1.12M$1.12M — vs Q2 2024−23.3% vs Q1 2025
Net Income-$52.59M-$52.59M N/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.41-$0.41 N/M vs Q2 2024N/M vs Q1 2025
Operating Income-$53,377,000N/M
Operating Cash Flowderived-$41,412,000N/M
Free Cash Flowderived-$42,984,000N/M
Margins · derived
Operating margin-4787.2%
Net margin-4716.7%
What the release said
The release
Same quarter
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Revenue | $1.12M | $0.00 | $0.00 | — |
| Net Income | -$52.59M | -$55.33M | -$42.39M | -$29.35M |
| EPS Diluted | -$0.41 | -$0.46 | -$0.47 | -$1.76 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR